EBV-associated nasopharyngeal carcinomas: From epidemiology to virus-targeting strategies

Trends in Microbiology

Volumn 12, Issue 8, 2004, Pages 356-360

  Busson, Pierre ^a   Keryer, Cécile ^a   Ooka, Tadamassa ^b   Corbex, Marilys ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE SILENCING; GENETIC PREDISPOSITION; HUMAN; LATENT PERIOD; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

DNA VIRUSES; HUMAN HERPESVIRUS 4;

EID: 3342875964     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2004.06.005     Document Type: Short Survey

References (31)

1. Edwards R.H., et al. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J. Virol. 78:2004;868-881
2. Scholle F., et al. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74:2000;10681-10689
3. Nanbo A., et al. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 21:2002;954-965
4. Tsimbouri P., et al. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene. 21:2002;5182-5187
5. Feng W.H., et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 62:2002;1920-1926
6. Ferlay, J. et al. (2001) GLOBOCAN 2000; Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase N°5, IARC Press, Lyon.
7. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 12:2002;421-429
8. Jeannel D., et al. Diet, living conditions and nasopharyngeal carcinoma in Tunisia: a case-control study. Int. J. Cancer. 46:1990;421-425
9. Chen C.J., et al. Cancer epidemiology and control in Taiwan: a brief review. Jpn. J. Clin. Oncol. 32:2002;S66-S81
10. Feng B.J., et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet. 31:2002;395-399
11. Xiong W., et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 64:2004;1972-1974
12. Jalbout M., et al. Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma. Cancer Lett. 193:2003;75-81
13. Hirunsatit R., et al. Polymeric immunoglobulin receptor polymorphisms and risk of nasopharyngeal cancer. BMC Genet. 4:2003;3
14. Dolcetti R., Menezes J. Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: new immunobiological and molecular insights on a long-standing etiopathogenic association. Adv. Cancer Res. 87:2003;127-157
15. Dardari R., et al. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int. J. Cancer. 92:2001;294-297
16. Mokni-Baizig N., et al. Association between HLA-A and -B antigens and -DRB1 alleles and nasopharyngeal carcinoma in Tunisia. Oncology. 61:2001;55-58
17. Nicholls J., et al. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. J. Virol. Methods. 116:2004;79-88
18. Raab-Traub A., et al. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12:2002;431-441
19. Decaussin G., et al. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res. 60:2000;5584-5588
20. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 12:2002;451-462
21. Thomas C., et al. The BZLF1 promoter of Epstein-Barr virus is controlled by E box- and HI-motif-binding factors during virus latency. J. Gen. Virol. 84:2003;959-964
22. Khabir A., et al. Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect. Prev. 27:2003;250-255
23. Pathmanathan R., et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333:1995;693-698
24. Murono S., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6905-6910
25. Sall, A. et al. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. Oncogene (in press).
26. Li J.H., et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol. Ther. 8:2003;964-973
27. Chia M., et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol. Ther. 9:2004;804-817
28. Lin C.L., et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62:2002;6952-6958
29. Li X.P., et al. Suppression of Epstein-Barr virus-encoded latent membrane protein-1 by RNA interference inhibits the metastatic potential of nasopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 315:2004;212-218
30. Farrell J.C., et al. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl. Acad. Sci. U. S. A. 101:2004;4625-4630
31. Jarver P., Langel U. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov. Today. 9:2004;395-402